by René Miguel Gonzalez, MD
Patients experience nausea and vomiting 30-50% of surgical recoveries! There are NO positive reviews from a patient that vomits post-surgery. PONV is costly in many ways including slowed patient recovery, poor patient experience and in increased staffing needs. Reducing PONV can help make hospitals and surgery centers become more productive, more pleasant and more profitable and anesthesia providers happier.
Aromatherapy from the vanilla infused Capnomask O2/CO2 mask is a safe and effective tool for anesthesia to use to reduce PONV, provide oxygen and monitor the patients breathing to assure safe MAC anesthesia.
The vanilla infused Capnomask offers a drug-free therapy to give anesthesia a proactive way to reduce the chance of a patient experiencing nausea and vomiting. The Capnomask offers other advantages including:
- Excellent patient oxygenation of over double the FiO2 of nasal oxygen canula.
- Capnomask acts as a physical shield or barrier reducing atomization of a patient’s exhalation thus protecting nurses, surgeons and anesthesia by reducing the spread of germs including Covid19.
- Capnomask comes preassembled with oxygen tubing and 10’ EtCO2 sample line to safely monitor a patient’s breathing to assure no hypoventilation incidents.
- Vanilla infused scent reduces nausea and vomiting reducing PONV.
- Low cost of Capnomask compared to cost of DIY or Do It Yourself options of converting a standard oxygen mask with IV catheter and adding an EtCO2 sample line.
- Reduced anesthesia time to set up DIY version for MAC cases.
Further benefits of the Capnomask:
- Reducing Costs
- Reduced staffing costs and resources used to administer and monitor PONV treatments
- Reduced drug costs and side effects of nausea prevention drugs
- Reduced involvement of pharmacy and medication costs
- Reduced length of recovery time and improved PACU throughput
- Improved HCAHPS scores with less PONV
- Adding Value
- Preventing nausea with the aromatherapy of Capnomask improves patient experience.
- Satisfaction scores improve with the reduction in PONV
- Less staff required for PONV intervention if prevented by proactively using Capnomask
- Capnomask may be considered an added component of ERAS or Enhanced Recovery after Surgery
Novaerus Defend 1050 cleared by FDA as 510(k) Class II Medical Device to inactivate and filter out airborne virus and bacteria for medical purposes
Defend 1050 uses patented NanoStrike® technology to damage and inactivate airborne micro-organisms.
Dublin, Ireland and Stamford, CT – Novaerus, a WellAir company that delivers clean air solutions to help prevent the spread of infectious outbreaks, announced today that the U.S. Food and Drug Administration (FDA) cleared the Novaerus Defend 1050 (NV 1050) as a 510(k) Class II Medical Device to inactivate and filter out micro-organisms, including virus and bacteria, for medical purposes. The Novaerus Defend 1050 is the first system that uses NanoStrike®, a patented plasma generating technology, to receive FDA 510(k) clearance.
The Novaerus Defend 1050 is a free-standing, portable recirculating air cleaning system designed for additional frontline protection in healthcare settings such as operating rooms, intensive care units, in vitro fertilization labs, emergency rooms, waiting and treatment areas, neonatal units, and other critical environments including those performing aerosol-generating medical procedures (AGMP).
The Defend 1050’s NanoStrike technology uses a plasma field that rapidly inactivates micro-organisms at the molecular level. Within 15 minutes, the Defend 1050 has demonstrated a 4-log (99.99%) reduction of the MS2 bacteriophage RNA virus, an accepted surrogate for SARS-CoV-2. The Defend 1050 also showed a 4-log (99.99%) reduction in Bacillus Globigii endospores (bacterial spores) within 15 minutes, which was maintained over the prolonged operation (24 hours).
The Defend 1050 is currently used in hospitals and healthcare settings worldwide. Given the rapid spread of COVID-19, WellAir moved quickly to understand how this device could potentially combat the virus while moving it through a thorough FDA medical device clearance process. Additionally, the Defend 1050 meets relevant performance criteria in the FDA Guidance, which provides non-binding recommendations that may reduce the risk of viral exposure for patients and healthcare providers during the current public health emergency.
“Our team of outstanding engineers and scientists have been focused on delivering innovative and powerful airborne infection control devices. The FDA clearance on the Defend 1050 is a critical milestone for our company, validating our work to deliver a safe and effective medical device,” said Dr Kevin Devlin, WellAir CEO. “The Defend 1050 has demonstrated tremendous efficacy in third party testing against viruses, bacteria, VOCs, and particulate matter, which makes it an ideal solution for hospitals and healthcare settings. As we continue to see an alarming rise in the number of COVID-19 cases, we have moved quickly to make the device readily available.”
Defend 1050 utilizes multiple stages to reduce airborne micro-organisms. The first stage is a general air pre-filter that captures particles between 4 and 10 microns from the input airflow. This filtered air passes through a series of NanoStrike coils (plasma generators) that damage and inactivate micro-organisms on contact, including viruses and bacteria. The resulting inactive particulates are trapped by a HEPA (High-efficiency Particulate Air) filter. In a final cleaning stage, an activated carbon filter traps VOCs in the airstream before the air is released into the environment.
The Defend 1050 system is delivered complete with all components necessary for immediate use. It can be wheeled easily by a single person to the desired point of use and plugs into standard outlets. Five airflow speed settings enable optimization to each healthcare environment. The only routine maintenance required is a calendar-based filter change schedule.
If you are a medical or healthcare facility interested in learning more about the Novaerus Defend 1050 or other Novaerus products, additional information can be found here, or please contact us
Alar Nasal Pulse Oximetry Sensor works on the most challenging patients!
“It works when other sensors fail.” The monitoring site is unaffected by non-invasive blood pressure measurements thus reducing false alarms and giving the anesthesia provider uninterrupted oximeter measurements. The Alar Nasal Pulse Oximetry Sensor can be left on for PACU and SICU providing oximeter measurements for the entire length of stay of the post-surgical patient saving the hospital thousands and enhancing patient comfort.
Reliable accuracy – unaffected by poor peripheral perfusion or low saturations
The Alar Nasal Pulse Oximetry Sensor fits comfortably on the fleshy part of the side of the nose. The site is fed by both the external and internal carotid arteries; the latter also provides blood to the brain. The rich vascular supply to this region provides a strong, reliable signal, even when it is difficult or impossible to get a signal at the fingertips.
Monitoring Site results in faster detection of oxygen saturation changes
Because the Alar Nasal Pulse Oximetry Sensor measures the oxygen saturation from a vessel also supplying blood to the brain, changes have been proven to be detected up to 30 seconds faster than with a finger sensor.
Improved patient comfort
The hands-free Alar Sensor does not impede normal patient functions such as eating, drinking or talking. It is less bothersome and is not likely to become disconnected.
Cost effective and convenient
The single-patient-use Alar Sensor does not use adhesives at the sensor site. The sensor can be removed and reapplied for up to 7 days saving hospitals up to $232 for the SICU patient. Proven accuracy reduces false alarms improving patient safety, patient satisfaction and nurse productivity.
Call 800-875-BELL(2355) for More Information.
Like other anesthesia pulse sensors, the Nasal Alar Pulse Oximetry Sensor from Bell Medical is designed for low profusion patients and multi-day stay ICU patients. The Nasal Alar Pulse Oximeter Probe is FDA approved for up to 28 days on a patient.
The Nasal Alar Pulse Oximeter Probe is lightweight and comfortable to wear. Patients LOVE IT!
Nasal Alar Pulse Oximetry Sensor works on the most challenging patients!
Reliable accuracy – unaffected by poor peripheral perfusion or low saturations with Nasal Alar Pulse Oximetry Sensor
This oxygen and pulse sensor fits comfortably on the fleshy part of the side of the nose. The site is fed by both the external and internal carotid arteries; the latter also provides blood to the brain. The rich vascular supply to this region provides a strong, reliable signal, even when it is difficult or impossible to get a signal at the fingertips.
Monitoring Site results in faster detection of oxygen saturation changes with Nasal Alar Pulse Oximetry Sensor
Because the Nasal Alar Pulse Oximeter Probe measures the oxygen saturation from a vessel also supplying blood to the brain, changes have been proven to be detected up to 30 seconds faster than with a finger sensor.
Improved patient comfort with Nasal Alar Pulse Oximetry Sensor
The hands-free Alar oxygen and pulse sensor does not impede normal patient functions such as eating, drinking, or talking. It is less bothersome to the patient and is not likely to become disconnected.
Cost effective and convenient with Nasal Alar Pulse Oximetry Sensor
The single-patient-use Alar Sensor does not use adhesives at the sensor site. The sensor can be removed and reapplied for up to 7 days saving hospitals up to $232 for the ICU patient. Proven accuracy reduces false alarms improving patient safety, patient satisfaction and nurse productivity.